Filsuvez has the potential to become the first treatment approved for epidermolysis bullosa, a rare genetic condition where skin can tear and blister at even the slightest touch.

With two revenue-generating products already on the market and Phase III data pending on Filsuvez for epidermolysis bullosa, CEO Joe Wiley has told Scrip that a US listing will give Amryt more visibility and credibility when it comes to future licensing and acquisition possibilities.

Pharma pays $100m up front and makes $20m equity investment for rights to three preclinical cancer programs. Plus more than 20 deal summaries, including COVID-19-related transactions.

Clinical trials across the board are being impacted by coronavirus and Syncona, the investment powerhouse behind a number of UK cell and gene therapy biotechs, says that its portfolio companies are facing considerable delays.